Liva Healthcare selected by NICE to Offer Hybrid Weight-Loss Programmes on the NHS

LONDON, United Kingdom, August 16, 2023

Liva is delighted to be provisionally selected as one of the leading digital therapeutics platforms to offer hybrid weight-loss programmes in partnership with the National Health Service (NHS).

The National Institute for Health and Care Excellence (NICE) has published new draft guidance that will allow NHS patients to be referred to digital weight management services and prescribed weight-loss medication. Liva is one of four digital therapeutics platforms that have been recommended to support patients throughout their treatment. NICE relied heavily on Liva’s extensive clinical evidence in drawing up the draft guidance for these new measures to tackle the obesity crisis.

Liva has a range of clinical studies showcasing remarkable results. Patients in one study lost 4.5kg in six months supported by Liva’s lifestyle change coaching platform. In contrast, those using conventional methods reported weight loss of only 1.5kg. Liva’s hybrid approach combines digital engagement with one to one clinical coaching and can be delivered at scale.

These programmes, endorsed by the National Institute for Health and Care Excellence (NICE), leverage the potential of these digital platforms. Accessible through apps and computers, they enable healthcare specialists to provide comprehensive care and support online. This innovative approach addresses the challenges posed by the limitations of traditional face-to-face services which are overburdened with long waiting lists to access services.

A consultation on the recommendations is taking place and NICE expect to publish final guidance on Thursday, 28 September 2023.

A Comprehensive Approach to Care

Liva’s solution brings together a team of specialists to address the lifestyle and behaviour change aspects of losing weight and improving wellbeing. Patients undergo a clinical assessment before embarking on their treatment journey – eligibility criteria include a BMI of 35 or over, coupled with at least one weight-related condition such as diabetes or high blood pressure. This individualised approach ensures that each patient receives tailored care that aligns with their specific needs.

Under the new scheme Liva will be able to prescribe weight-loss injections as part of the programme, a pivotal aspect of the treatment. These injections, such as semaglutide and liraglutide (known as Wegovy and Saxenda respectively), are accompanied by a reduced calorie diet and exercise plan. These medications have already shown promise, with Wegovy from Novo Nordisk demonstrating a potential 20% reduction in the risk of heart attacks and strokes for obese patients with cardiovascular disease. This groundbreaking advancement holds the potential to change lives and shift the trajectory of health outcomes.

A Vision for the Future

The impact of these digital solutions goes beyond personal transformations. NICE estimates that up to 48,000 individuals will gain access to these virtual services, potentially saving a staggering 145,000 hours of clinician time. The NHS is accelerating the adoption of pioneering digital-first services across a range of conditions, and this latest step will see new evidence-based companies working to support NHS patients with cardiometabolic conditions.

Liva’s evidence-based, digital lifestyle change platform is supporting people on the journey to a diabetes-free life. Studies conducted in the UK and Denmark show that 47% of people with prediabetes reversed their condition in 12 months and 39% of people living with type 2 diabetes reversed their condition to a normal range. An astonishing 80% of people with diabetes on Liva’s platform reduce their HbA1c levels.

About Liva Healthcare

Liva is a leading digital therapeutics company that advances digital-first delivery of behaviour change programmes to improve health outcomes globally, at scale. Our team of dedicated healthcare professionals create personalised change programmes to support people in their journey to prevent, manage and treat obesity, type-2 diabetes and prediabetes and other cardiometabolic conditions.

The safety and efficacy of our digital therapeutic programmes are well-supported by extensive evidence from randomised controlled trials (RCTs) and other real-world evidence studies. Liva’s innovative digital-first coaching platform integrates seamlessly into healthcare systems offering personalised clinical support to more than 45,000 people.

Founded in Denmark, we have expanded our reach across multiple geographies, marking our presence as a global force for advancing better health outcomes. Our collaborations with healthcare systems, including the NHS, as well as partnerships with some of the world’s largest life science companies and health insurers allow us to impact lives on a large scale.

Please visit and follow us on Linkedin on @LivaHealth.

Media Enquiries – English

Sian Jarvis, CB, FRCGP(H)
Chief Marketing Officer
+447867 538399

Stephen Hankinson
Marketing Director

Mediekontakt – Dansk

Sarah Andreassen
Marketing Manager


Related articles